ALX Oncology Holdings Inc

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. The company’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, ADCs and PD-1/PD-L1 immune checkpoint inhibitors.